In terms of the control of blood sugar and reduced insulin resistance, an insulin pump (CSII) combined with biguanide, DPP-4 inhibitors, sensitizers, and GLP-1 receptor agonists can further reduce FPG, 2hPG, and HOMA-IR levels compared with an insulin pump alone [9,21,22,23,24,25]. This evidence concerns the gene DPP4 and Insulin resistance.